Ep. 368 - ASCO Preview, China Policy, ADC Linkers – BioCentury This Week

At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to the cancer. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Revolution’s daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury’s radar at this year’s American Society of Clinical Oncology meeting. BioCentury’s a...

Poddgruvan

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Ep. 374 - Parkinson's deep dive & FDA trial reforms

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Ep. 371 - Moving faster at the academia-industry interface

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs